{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T20:58:55Z","timestamp":1777409935145,"version":"3.51.4"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.bbrc.2022.11.038","type":"journal-article","created":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T02:13:35Z","timestamp":1668478415000},"page":"267-275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Dual PI3K\u03b4\u03b3 inhibition demonstrates potent anticancer effects in diffuse large B-cell lymphoma models: Discovery and preclinical characterization of LL-00084282"],"prefix":"10.1016","volume":"637","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8487-9387","authenticated-orcid":false,"given":"Mahip K.","family":"Verma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charudatt","family":"Samant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramesh","family":"Kale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sukanya","family":"Patra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nilesh","family":"Mahajan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3309-9054","authenticated-orcid":false,"given":"Milind K.","family":"Gholve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajitkumar","family":"Marisetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brahmam","family":"Sunkara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aditya","family":"Naik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manisha","family":"Shingare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhusudhan","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anand M.","family":"Bokare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atul","family":"Akarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarita","family":"Koul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prashant B.","family":"Nigade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinod B.","family":"Patil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dipak","family":"Modi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prajakta","family":"Ahirrao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shashikant","family":"Pawar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0992-363X","authenticated-orcid":false,"given":"Sandip","family":"Kuldharan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1809-4944","authenticated-orcid":false,"given":"Lal","family":"Dinchhana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maneesh","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayasagar","family":"Gundu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nirmal","family":"Jana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prashant","family":"Vidhate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachin Jaysing","family":"Mahangare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1735-7965","authenticated-orcid":false,"given":"Manojkumar R.","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajan N.","family":"Goel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mandar","family":"Bhonde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajender Kumar","family":"Kamboj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venkata P.","family":"Palle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2022.11.038_bib1","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.yexmp.2018.11.008","article-title":"Molecular and cellular genetics of non-Hodgkin lymphoma: diagnostic and prognostic implications","volume":"106","author":"Pratap","year":"2019","journal-title":"Exp. Mol. Pathol."},{"key":"10.1016\/j.bbrc.2022.11.038_bib2","article-title":"Epidemiology of non-hodgkin's lymphoma","volume":"9","author":"Thandra","year":"2021","journal-title":"Med Sci (Basel)"},{"key":"10.1016\/j.bbrc.2022.11.038_bib3","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.pathol.2017.09.006","article-title":"Diffuse large B-cell lymphoma","volume":"50","author":"Li","year":"2018","journal-title":"Pathology"},{"key":"10.1016\/j.bbrc.2022.11.038_bib4","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2022.11.038_bib5","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.bbrc.2022.11.038_bib6","first-page":"55","article-title":"B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies","volume":"14","author":"Koehrer","year":"2016","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"10.1016\/j.bbrc.2022.11.038_bib7","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41375-020-01072-6","article-title":"Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances","volume":"35","author":"Wen","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2022.11.038_bib8","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1002\/med.21799","article-title":"MALT1 as a promising target to treat lymphoma and other diseases related to MALT1 anomalies","volume":"41","author":"Liang","year":"2021","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bbrc.2022.11.038_bib9","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/14728222.2018.1420782","article-title":"BCL6 as a therapeutic target for lymphoma","volume":"22","author":"Leeman-Neill","year":"2018","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.bbrc.2022.11.038_bib10","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1084\/jem.20020805","article-title":"A\u00a0crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation","volume":"196","author":"Clayton","year":"2002","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.bbrc.2022.11.038_bib11","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/s41598-018-19460-5","article-title":"PI3K induces B-cell development and regulates B cell identity","volume":"8","author":"Abdelrasoul","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrc.2022.11.038_bib12","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1146\/annurev.biochem.70.1.535","article-title":"Synthesis and function of 3-phosphorylated inositol lipids","volume":"70","author":"Vanhaesebroeck","year":"2001","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.bbrc.2022.11.038_bib13","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3389\/fimmu.2012.00224","article-title":"The phosphoinositide 3-kinase signaling pathway in normal and malignant B cells: activation mechanisms, regulation and impact on cellular functions","volume":"3","author":"Pauls","year":"2012","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrc.2022.11.038_bib14","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature19834","article-title":"PI3Kgamma is a molecular switch that controls immune suppression","volume":"539","author":"Kaneda","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2022.11.038_bib15","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.2147\/OTT.S187459","article-title":"Rapid and complete response to idelalisib in a case of Richter syndrome","volume":"12","author":"Bagacean","year":"2019","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.bbrc.2022.11.038_bib16","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/S2352-3026(18)30196-0","article-title":"Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study","volume":"6","author":"Davids","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.bbrc.2022.11.038_bib17","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood-2017-05-786566","article-title":"Duvelisib, a novel oral dual inhibitor of PI3K-delta,gamma, is clinically active in advanced hematologic malignancies","volume":"131","author":"Flinn","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2022.11.038_bib18","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1007\/s40265-018-1013-4","article-title":"Duvelisib: first global approval","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.bbrc.2022.11.038_bib19","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/aps.2015.71","article-title":"PI3K isoform-selective inhibitors: next-generation targeted cancer therapies","volume":"36","author":"Wang","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bbrc.2022.11.038_bib20","first-page":"821","article-title":"PI3K inhibitors: understanding toxicity mechanisms and management","volume":"31","author":"Greenwell","year":"2017","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.bbrc.2022.11.038_bib21","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1016\/j.bmcl.2013.06.052","article-title":"Identification of GNE-293, a potent and selective PI3Kdelta inhibitor: navigating in\u00a0vitro genotoxicity while improving potency and selectivity","volume":"23","author":"Safina","year":"2013","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.bbrc.2022.11.038_bib22","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1038\/onc.2011.42","article-title":"PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs","volume":"30","author":"Weigelt","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2022.11.038_bib23","doi-asserted-by":"crossref","first-page":"7584","DOI":"10.1158\/1078-0432.CCR-17-0676","article-title":"Inhibiting PI3Kbeta with AZD8186 regulates key metabolic pathways in PTEN-null tumors","volume":"23","author":"Lynch","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2022.11.038_bib24","doi-asserted-by":"crossref","first-page":"4468","DOI":"10.1167\/iovs.08-1781","article-title":"Suppression of activation and induction of apoptosis in RAW264.7 cells by amniotic membrane extract","volume":"49","author":"He","year":"2008","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.bbrc.2022.11.038_bib25","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ajh.25460","article-title":"Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment","volume":"94","author":"Liu","year":"2019","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bbrc.2022.11.038_bib26","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1126\/science.1153629","article-title":"Oncogenic CARD11 mutations in human diffuse large B cell lymphoma","volume":"319","author":"Lenz","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2022.11.038_bib27","doi-asserted-by":"crossref","first-page":"13447","DOI":"10.1073\/pnas.1514944112","article-title":"Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens","volume":"112","author":"Young","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbrc.2022.11.038_bib28","first-page":"23","article-title":"FDA evaluating possible serious risks from umbralisib","volume":"122","author":"Aschenbrenner","year":"2022","journal-title":"Am. J. Nurs."},{"issue":"5","key":"10.1016\/j.bbrc.2022.11.038_bib29","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/CCO.0000000000000871","article-title":"Current status of phosphoinotiside-3 kinase inhibitors in blood cancers","volume":"34","author":"Shouse","year":"2022","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.bbrc.2022.11.038_bib30","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1126\/science.1073560","article-title":"Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice","volume":"297","author":"Okkenhaug","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2022.11.038_bib31","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1182\/blood-2015-12-683516","article-title":"Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL","volume":"127","author":"Barr","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2022.11.038_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083830","article-title":"The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells","volume":"8","author":"Fiorcari","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2022.11.038_bib33","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1126\/science.287.5455.1040","article-title":"Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration","volume":"287","author":"Sasaki","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2022.11.038_bib34","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1038\/s41375-018-0012-5","article-title":"Distinct roles for phosphoinositide 3-kinases gamma and delta in malignant B cell migration","volume":"32","author":"Ali","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2022.11.038_bib35","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.chembiol.2013.09.017","article-title":"PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models","volume":"20","author":"Winkler","year":"2013","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bbrc.2022.11.038_bib36","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.jaci.2008.11.047","article-title":"Allergic airway hyperresponsiveness, inflammation, and remodeling do not develop in phosphoinositide 3-kinase gamma-deficient mice","volume":"123","author":"Takeda","year":"2009","journal-title":"J.\u00a0Allergy Clin. Immunol."},{"key":"10.1016\/j.bbrc.2022.11.038_bib37","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.ajpath.2012.01.030","article-title":"PI3 kinase delta is a key regulator of synoviocyte function in rheumatoid arthritis","volume":"180","author":"Bartok","year":"2012","journal-title":"Am. J. Pathol."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X2201587X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X2201587X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T14:45:37Z","timestamp":1762094737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X2201587X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":37,"alternative-id":["S0006291X2201587X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2022.11.038","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual PI3K\u03b4\u03b3 inhibition demonstrates potent anticancer effects in diffuse large B-cell lymphoma models: Discovery and preclinical characterization of LL-00084282","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2022.11.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}